Faron Banner Image


  • Ticker FARN
    Exchange LSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Faron Logo Image
  • 11-50 Employees
  • Based in Turku, Finland
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratoryMore distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.
4.7 / 5.0 (63)

Faron reports have an aggregate usefulness score of 4.7 based on 63 reviews.


Most Recent Annual Report

MOST RECENT 2023 Annual Report

Older/Archived Annual Reports

Faron Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!